1. Measurement of serum pralidoxime methylsulfate (Contrathion®) by high-performance liquid chromatography with electrochemical detection
- Author
-
François Scherninski, Pascal Houzé, Bernard Bousquet, Bernard Gourmel, Stephen W. Borron, and Frédéric J. Baud
- Subjects
Cholinesterase Reactivators ,Pralidoxime ,Clinical Biochemistry ,Electrochemical detection ,Buffers ,Sensitivity and Specificity ,Biochemistry ,Organophosphate poisoning ,High-performance liquid chromatography ,Loading dose ,Biological fluid ,Analytical Chemistry ,Electrochemistry ,medicine ,Humans ,Chromatography, High Pressure Liquid ,Pralidoxime Compounds ,Chromatography ,Contrathion ,Human studies ,Chemistry ,Reproducibility of Results ,Cell Biology ,General Medicine ,medicine.disease ,medicine.drug - Abstract
Pralidoxime methylsulfate (Contrathion) is widely used to treat organophosphate poisoning. Despite animal and human studies, the usefulness of Contrathion therapy remains a matter of debate. Therapeutic dosage regimens need to be clarified and availability of a reliable method for plasma pralidoxime quantification would be helpful in this process. We here describe a high-performance liquid chromatography technique with electrochemical detection to measure pralidoxime concentrations in human serum using guanosine as an internal standard. The assay was linear between 0.25 and 50 microg mL(-1) with a quantification limit of 0.2 microg mL(-1). The analytical precision was satisfactory, with variation coefficients lower 10%. This assay was applied to the analysis of a serum from an organophosphorate poisoned patient and treated by Contrathion infusions (100 and 200 mg h(-1)) after a loading dose (400 mg).
- Published
- 2005